Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.58 |
| ▸ | DPP4 | P27487 | 6/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9054356 | 0.84 | ALDH1A1 (0.51) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL2694035 | 0.82 | DPP7 (0.64) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL14850854 | 0.82 | ALDH1A1 (0.55) | DPP7DPP8DPP9DPP4MEN1 | |
| SCHEMBL29049118 | 0.82 | DPP7 (0.64) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL6752685 | 0.80 | DPP7 (0.62) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL15247209 | 0.80 | DPP7 (0.58) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL24324253 | 0.80 | DPP4 (0.55) | DPP7DPP8DPP9DPP4MEN1 | |
| SCHEMBL24322510 | 0.80 | DPP4 (0.55) | DPP7DPP8DPP9DPP4MEN1 | |
| SCHEMBL7318947 | 0.79 | DPP4 (0.50) | DPP7DPP8DPP9DPP4FAP | |
| SCHEMBL15247211 | 0.78 | DPP7 (0.56) | DPP7DPP8DPP9DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP7 367/4885DPP8 296/4885DPP9 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.